Invariance principle, multifractional Gaussian processes and long-range dependence

This paper is devoted to establish an invariance principle where the limit process is a multifractional Gaussian process with a multifractional function which takes its values in $(1/2,1)$. Some properties, such as regularity and local self-similarity of this process are studied. Moreover the limit process is compared to the multifractional Brownian motion.Comment: Published in at http://dx.doi.org/10.1214/07-AIHP127 the Annales de l'Institut Henri Poincar\'e - Probabilit\'es et Statistiques (http://www.imstat.org/aihp/) by the Institute of Mathematical Statistics (http://www.imstat.org

Experience with statically-generated proxies for facilitating Java runtime specialisation

Issues pertaining to mechanisms which can be used to change the behaviour of Java classes at runtime are discussed. The proxy mechanism is compared to, and contrasted with other standard approaches to this problem. Some of the problems the proxy mechanism is subject to are expanded upon. The question of whether statically-developed proxies are a viable alternative to bytecode rewriting was investigated by means of the JavaCloak system, which uses statically-generated proxies to alter the runtime behaviour of externally-developed code. The issues addressed include ensuring the type safety, dealing with the self problem, object encapsulation, and issues of object identity and equality. Some performance figures are provided which demonstrate the load the JavaCloak proxy mechanism places on the system

Utilisation des infrastructures de la Grille EGI pour les simulations de CTA

Utilisation des infrastructures de la Grille EGI pour les simulations de CT

DIRAC framework evaluation for the Fermi\boldsymbol{Fermi}-LAT and CTA experiments

DIRAC (Distributed Infrastructure with Remote Agent Control) is a general framework for the management of tasks over distributed heterogeneous computing environments. It has been originally developed to support the production activities of the LHCb (Large Hadron Collider Beauty) experiment and today is extensively used by several particle physics and biology communities. Current ($Fermi$ Large Area Telescope -- LAT) and planned (Cherenkov Telescope Array -- CTA) new generation astrophysical/cosmological experiments, with very large processing and storage needs, are currently investigating the usability of DIRAC in this context. Each of these use cases has some peculiarities: $Fermi$-LAT will interface DIRAC to its own workflow system to allow the access to the grid resources, while CTA is using DIRAC as workflow management system for Monte Carlo production and analysis on the grid. We describe the prototype effort that we lead toward deploying a DIRAC solution for some aspects of $Fermi$-LAT and CTA needs.Comment: proceedings to CHEP 2013 conference : http://www.chep2013.org

Demographic Change in European Towns 2001–11: A Cross-National Multi-Level Analysis

© 2017 Royal Dutch Geographical Society KNAG The unique contribution of this paper is to empirically compare and contrast demographic change in settlements with a population between 5,000 and under 50,000 (defined as towns) across different national urban systems in Europe with common definitions for the first time. The analysis uses a new data set based on harmonised small area data and harmonised morphological definitions of what a town is. The paper hypothesises first that a general model of demographic growth can be applied across national urban systems and secondly that regional demographic change is a significant predictor of demographic change in towns nested within those regions within this generalised model. A fixed effect multi-level regression analysis tests the importance of town-level and regional factors among towns from five national systems but also within two individual national urban systems. The findings suggest that national context still matters and within some national systems, regional context also strongly predicts demographic change in towns

Ireland's Rejection of the Lisbon Treaty and the EU's Impasse.

non

Clinical Remission in Oral Corticosteroid (OCS)-dependent Patients with Severe Asthma : An Analysis of the ANDHI-IP and PONENTE Trials

Funding: This study was funded by AstraZeneca (Cambridge, UK).Peer reviewe

Nasal High Flow at 25 L/min or Expiratory Resistive Load Do Not Improve Regional Lung Function in Patients With COPD: A Functional CT Imaging Study

BackgroundNasal high flow (NHF) is a non-invasive breathing therapy that is based on the delivery via a large-caliber nasal cannula of heated and humidified air at flow rates that exceed peak inspiratory flow. It is thought that positive airway pressure generated by NHF can help reduce gas trapping and improve regional lung ventilation. There are no data to confirm this hypothesis at flow rates applicable in stable chronic obstructive pulmonary disease (COPD) patients.MethodsIn this study, we used non-rigid registration of computed tomography (CT) images acquired at maximal expiration and inspiration to compute regional lung attenuation changes (ΔHU), and lung displacement (LD), indices of regional lung ventilation. Parametric response maps (Galban et al., 2012) were also computed in each experimental condition. Eight COPD patients were assessed at baseline (BL) and after 5 min of NHF and expiratory resistive loading (ERL).ResultsΔHU was: BL (median, IQR): 85 (67.2, 102.8); NHF: 90.7 (57.4, 97.6); ERL: 74.6 (46.4, 89.6) HU (p = 0.531); and LD: 27.8 (22.3, 39.3); 17.6 (15.4, 27.9); and 20.4 (16.6, 23.6) mm (p = 0.120) in the 3 conditions, respectively. No significant difference in trapping was observed. Respiratory rate significantly decreased with both treatments [BL: 17.3 (16.4, 18.9); NHF: 13.7; ERL: 11.4 (9.6, 13.2) bpm; and p < 0.001].ConclusionNeither NHF at 25 L/min nor ERL significantly improved the regional lung ventilation of stable COPD patients with gas trapping, based on functional lung CT imaging. Further study including more subjects is needed to assess the potential effect of NHF on regional lung function at higher flow rates.Clinical Trial Registrationwww.clinicaltrials.gov/under, identifier NCT03821311